article thumbnail

FDA AdCom votes in favour of Lundbeck’s/Otsuka’s Rexulti in AAD

Pharmaceutical Technology

The current unmet need, the benefit of treatment with Rexulti, and a reasonable safety profile persuaded Dr. Merit Cudkowicz, Julieanne Dorn professor of neurology at Harvard University’s Medical School, to give a positive vote.

FDA 96
article thumbnail

Citrate-free HCF of adalimumab biosimilar gets positive opinion

European Pharmaceutical Review

The study met all its primary objectives, demonstrating comparable pharmacokinetics and showing similar safety and immunogenicity between the two concentrations. In 2015, the EMA and US Food and Drug Administration (FDA) approved Humira ® HCF, which contains adalimumab at a concentration of 100mg/ml.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

EMA validates first regulatory submission for CRISPR-based medicine

European Pharmaceutical Review

Clinical trials for exa-cel The ongoing Phase I/II/III open-label trials, CLIMB-111 and CLIMB-121, are designed to assess the safety and efficacy of a single dose of exa-cel, the CRISPR-based medicine, in patients ages 12 to 35 years with TDT or with SCD, respectively.

Medicine 111
article thumbnail

Drug pricing increases are disgraceful

World of DTC Marketing

In November 2017, a study published in JAMA Internal Medicine examined the costs of developing 10 cancer drugs approved by the FDA from 2006 to 2015 and provided a strong contrast to the Tufts study from a year before. After all, 90 percent of all drugs that enter human testing fail.

Insurance 181
article thumbnail

MicroPort Navibot Receives 510(K) Clearance for its SkyWalker™ Robot-Assisted Platform for Orthopedic Applications

Legacy MEDSearch

The SkyWalker System has the technical advantages of precise operation and efficient coordination, while prioritizing safety. was established in China in 2015 and is a subsidiary of MicroPort Scientific Corporation. NaviBot is subsidiary of MicroPort MedBot. About MicroPort MedBot Shanghai MicroPort MedBot (Group) Co.,

article thumbnail

Senju Pharmaceutical and Novaliq close agreement for dry eye disease therapy

Pharmaceutical Technology

The therapy has shown efficacy and safety in trials for patients with a history of dry eye disease and clinical Meibomian gland dysfunction. Its safety and efficacy have been demonstrated in numerous studies in Europe, the United States and China. to treat dry eye disease.

article thumbnail

Tackling fake pharmaceuticals: an industry united against counterfeit products

European Pharmaceutical Review

According to the latest WHO estimates in 2015, this duped consumer base accounts for 50 percent of all online drug purchases. Revealing any unauthorised journeys or interventions helps to ensure patient safety and allows manufacturers to reap the rewards of cost savings and reputation management. 2015 Oct;386(10001):1327–8.